BioVersys Achieves Promising Results in Phase 2a Study of Novel Tuberculosis Treatment

BioVersys Reports Promising Results from ENABLE Study



In a significant stride towards advancing tuberculosis treatment, BioVersys AG has announced positive outcomes from its Phase 2a ENABLE study, which evaluated the compound AlpE, a new treatment regimen combining alpibectir with ethionamide. The study's results were presented at the Union World Conference on Lung Health, held from November 17 to 20, 2026, in Rio de Janeiro, Brazil, showcasing the promising early efficacy of AlpE in combating drug-sensitive pulmonary tuberculosis.

Study Overview


The ENABLE study investigated the bactericidal activity of AlpE among patients newly diagnosed with drug-sensitive pulmonary tuberculosis. The trial included a 14-day regimen comparing various dosages of alpibectir combined with ethionamide against standard treatments. Notably, 45 mg of alpibectir was evaluated alongside either 125 mg or 250 mg of ethionamide, marking a crucial progression in understanding its effectiveness.

All treatment regimens demonstrated early bactericidal activity, with findings indicating that the bactericidal effect was dependent on ethionamide dosage. The regimen incorporating 250 mg ethionamide showcased greater efficacy than the 125 mg alternative. While the study was not formally designed for direct comparisons, the AlpE regimen with 250 mg ethionamide displayed efficacy results comparable to the standard HRZE protocol, potentially positioning AlpE as a viable replacement for isoniazid in treating isoniazid-resistant tuberculosis.

Support for Future Evaluations


The encouraging results are crucial for ongoing investigational efforts with AlpE. Dr. David Barros-Aguirre from GSK emphasized that these findings contribute to the growing clinical evidence supporting AlpE's potential role in future tuberculosis regimens. Collaboratively developed by GSK and BioVersys, AlpE aims to offer simpler, more effective treatment alternatives for individuals affected by tuberculosis.

BioVersys' CEO, Dr. Marc Gitzinger, remarked on the importance of these results in advancing AlpE towards broader clinical use. He acknowledged the contributions from patients, investigators, and collaborators that made the trial possible, underlining the significance of private-public partnerships in innovating healthcare solutions.

Role of Public Funding and Collaborations


The ENABLE study was conducted as part of the European Union’s Innovative Health Initiative Joint Undertaking project UNITE4TB, with the backing of various funding agencies including IMI, EDCTP, and others. This collaboration reflects the commitment to enhance treatment options for tuberculosis patients and demonstrates how research initiatives can lead to meaningful advancements in global health.

Insights into Alpibectir


Alpibectir, formerly known as BVL-GSK098, is a novel antibacterial agent designed to enhance the efficacy of existing anti-tuberculosis medication. Developed through a unique approach that utilizes BioVersys' Transcriptional Regulatory Inhibitory Compounds (TRIC) technology, Alpibectir’s mechanism works by magnifying the effectiveness of ethionamide, ultimately facilitating better patient outcomes while potentially minimizing side effects.

The potential of AlpE as a treatment option is particularly significant, as it has already received orphan-drug designation from the FDA and EMA, which facilitates its expedited development and market access due to the urgent need for effective tuberculosis treatments.

Conclusion


The findings from the Phase 2a ENABLE study are a beacon of hope in the ongoing battle against tuberculosis. With the support of innovative partnerships and public funding, BioVersys aims to further unravel the potential of AlpE in treating this global health threat. As research continues, the integration of AlpE into treatment protocols could revolutionize therapy for millions affected by tuberculosis worldwide.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.